{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+B&page=8",
    "query": {
      "intervention": "High Dose Drug B",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 266,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+B&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+Dose+Drug+B&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T22:55:19.055Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01218620",
      "title": "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Gamma-Secretase Inhibitor RO4929097",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Tolbutamide",
          "type": "DRUG"
        },
        {
          "name": "Dextromethorphan Hydrobromide",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2010-09",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2014-12-23",
      "last_synced_at": "2026-11-10T22:55:19.055Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01218620"
    },
    {
      "nct_id": "NCT02013167",
      "title": "Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 405,
      "start_date": "2014-01-03",
      "completion_date": "2017-03-14",
      "has_results": true,
      "last_update_posted_date": "2024-03-05",
      "last_synced_at": "2026-11-10T22:55:19.055Z",
      "location_count": 16,
      "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013167"
    },
    {
      "nct_id": "NCT05129475",
      "title": "Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "PF-07321332/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2021-11-12",
      "completion_date": "2022-01-12",
      "has_results": true,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-11-10T22:55:19.055Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05129475"
    },
    {
      "nct_id": "NCT05787002",
      "title": "A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "AZD0780",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 16,
      "start_date": "2023-03-09",
      "completion_date": "2023-05-15",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-11-10T22:55:19.055Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05787002"
    },
    {
      "nct_id": "NCT01993017",
      "title": "Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Coronary Syndrome",
        "Depressive Symptoms"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy (CBT)",
          "type": "OTHER"
        },
        {
          "name": "Antidepressant Medication",
          "type": "DRUG"
        },
        {
          "name": "Standard Care",
          "type": "OTHER"
        },
        {
          "name": "Depressive symptom screener",
          "type": "OTHER"
        },
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 1501,
      "start_date": "2013-11",
      "completion_date": "2019-07-31",
      "has_results": true,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-11-10T22:55:19.055Z",
      "location_count": 4,
      "location_summary": "Bloomington, Minnesota • New York, New York • Henderson, North Carolina + 1 more",
      "locations": [
        {
          "city": "Bloomington",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Henderson",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01993017"
    },
    {
      "nct_id": "NCT04036682",
      "title": "A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "EGFR Exon 20 Mutation"
      ],
      "interventions": [
        {
          "name": "CLN-081",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cullinan Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 284,
      "start_date": "2019-10-31",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-11-10T22:55:19.055Z",
      "location_count": 18,
      "location_summary": "Anaheim, California • Duarte, California • Irvine, California + 12 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04036682"
    },
    {
      "nct_id": "NCT05395117",
      "title": "A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD5462",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2022-06-30",
      "completion_date": "2022-09-12",
      "has_results": false,
      "last_update_posted_date": "2023-12-13",
      "last_synced_at": "2026-11-10T22:55:19.055Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05395117"
    },
    {
      "nct_id": "NCT03386721",
      "title": "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers"
      ],
      "interventions": [
        {
          "name": "simlukafusp alfa",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 256,
      "start_date": "2018-02-19",
      "completion_date": "2021-12-30",
      "has_results": true,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-11-10T22:55:19.055Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Newnan, Georgia",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03386721"
    },
    {
      "nct_id": "NCT02287311",
      "title": "Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hodgkin Disease",
        "Non-Hodgkin Lymphoma",
        "Severe Chronic Active Epstein Barr Virus",
        "T/NK-lymphoproliferative Disease",
        "Nasopharyngeal Carcinoma",
        "Smooth Muscle Tumor"
      ],
      "interventions": [
        {
          "name": "MABEL CTLs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 38,
      "start_date": "2015-02",
      "completion_date": "2029-03",
      "has_results": true,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-11-10T22:55:19.055Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287311"
    },
    {
      "nct_id": "NCT05491733",
      "title": "A Bioequivalence Study of APX001 High-load and Low-load Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Invasive Fungal Infections"
      ],
      "interventions": [
        {
          "name": "APX001",
          "type": "DRUG"
        },
        {
          "name": "APX001A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2021-03-02",
      "completion_date": "2021-06-23",
      "has_results": false,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-11-10T22:55:19.055Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05491733"
    }
  ]
}